MDS Symposium | Conference

Dr. Garcia-Manero on Deferasirox in Iron Chelation Therapy for MDS

May 7th 2015

Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses deferasirox (Exjade) in iron chelation therapy for patients with myelodysplastic syndromes (MDS).

Eltrombopag Effectively Treats Cytopenias in MDS

May 2nd 2015

Treatment with the thrombopoietin receptor agonist eltrombopag significantly improved cytopenias and was well-tolerated in patients with low to intermediate-2 risk myelodysplastic syndromes.

Somatic Mutations Could Predict Response to Hypomethylating Agents in MDS

May 2nd 2015

A biomarker model that incorporates the mutational status of multiple somatic genes could be used to predict response to hypomethylating agents for patients with myelodysplastic syndromes.

IPSS Risk and EPO Levels Predict Response to ESAs in MDS

May 2nd 2015

Serum erythropoietin levels and risk by IPSS were predictive of response to erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.

Dr. Gail Roboz on Molecular Mutations in MDS

May 2nd 2015

Gail J. Roboz, MD, associate professor of Medicine, director, Leukemia Program, Weill Medical College of Cornell University, New York-Presbyterian Hospital, discusses the growing field of molecular mutations in myelodysplastic syndromes (MDS).

Dr. Zeidan on Subsequent MDS in Prostate Cancer Patients After Radiotherapy

May 2nd 2015

Amer Zeidan, MBBS, MHS, assistant professor of Medicine, Hematology, Yale Cancer Center, discusses a population-based study of subsequent myelodysplastic syndromes (MDS) in prostate cancer patients after radiotherapy.

T-Cell Depleted Allografts Lessen GVHD in MDS

May 1st 2015

Treatment with T-cell depleted transplantation was associated with a lower incidence of acute graft versus host disease (GVHD) and a very low incidence of chronic GVHD compared with unmodified allografts in patients with advanced myelodysplastic syndrome.

Lenalidomide Improves Quality of Life in Non-Del5q MDS

May 1st 2015

Treatment with lenalidomide (Revlimid) versus placebo improved health-related quality of life (HRQoL) after 24 weeks for patients with myelodysplastic syndromes.

Supportive Care Remains Backbone of Treatment in MDS

May 1st 2015

Treatment strategies for patients with myelodysplastic syndromes are built upon a foundation of supportive care, which consists of transfusions, iron chelation, and growth factor therapy.

Sara Tinsley Discusses Quality of Life in Patients with High-Risk MDS

May 1st 2015

Sara M. Tinsley, MS, PhD, ARNP, AOCN, nurse practitioner, malignant hematology, Moffitt Cancer Center, discusses a study that examined quality of life in patients with high-risk myelodysplastic syndromes (MDS).